Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer.

[1]  S. North,et al.  Medical Oncology , 2001, Sarcoma.

[2]  E. Van Cutsem,et al.  Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Goldberg,et al.  Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  P. Vrignaud,et al.  Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice , 1996, Anti-cancer drugs.

[5]  D. V. Von Hoff,et al.  Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Rothenberg.  CPT-11: an original spectrum of clinical activity. , 1996, Seminars in oncology.

[7]  F. di Costanzo,et al.  Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  T. Taguchi,et al.  [Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group]. , 1994, Gan to kagaku ryoho. Cancer & chemotherapy.

[9]  U. Haglund,et al.  Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  H. Wieand,et al.  Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Petroianu,et al.  Modified therapy with 5‐fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer , 1993, Cancer.

[12]  D. Shin,et al.  A phase III randomized study of 5‐fluorouracil and cisplatin versus 5‐fluorouracil, doxorubicin, and mitomycin C versus 5‐fluorouracil alone in the treatment of advanced gastric cancer , 1993, Cancer.

[13]  M. Fukuoka,et al.  CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Y. Miura,et al.  Effects of CPT‐11 in combination with other anti‐cancer agents in culture , 1992, International journal of cancer.

[15]  M. Buyse,et al.  Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  H. Wilke,et al.  Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  T. Tanaka,et al.  Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors. , 1987, Cancer research.

[18]  R. Golding,et al.  Prospective study on the dose relationship of mitomycin C–induced interstitial pneumonitis , 1987, Cancer.

[19]  Y. Suzuki,et al.  Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[20]  H. Averette,et al.  Cell kinetics and programmed chemotherapy for gynecologic cancer. I. Squamous-cell carcinoma. , 1976, American journal of obstetrics and gynecology.

[21]  R J Reitemeier,et al.  Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. , 1972, Cancer chemotherapy reports.

[22]  A. Guarino,et al.  Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). , 1970, Cancer chemotherapy reports.

[23]  L. Simon,et al.  Cancer of the stomach. , 1951, Connecticut state medical journal.

[24]  I. Hyodo,et al.  Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  T. Hickish,et al.  Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. Ohtsu,et al.  Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: report from the Japan Clinical Oncology Group (JCOG). , 1994, European journal of cancer.

[27]  T. Furuta,et al.  [Effect of administration schedules on the antitumor activity of CPT-11, a camptothecin derivative]. , 1990, Gan to kagaku ryoho. Cancer & chemotherapy.

[28]  J. Verweij,et al.  Mitomycin C-induced hemolytic uremic syndrome. Six case reports and review of the literature on renal, pulmonary and cardiac side effects of the drug. , 1987, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[29]  E. Nordman,et al.  Renal complications of mitomycin C therapy with special reference to the total dose. , 1985, Cancer.

[30]  A. Mittelman,et al.  Renal toxicity in man treated with mitomycin C , 1971, Cancer.